Erasca widens quarterly loss as R&D spending climbs
The biotechnology company reported a net loss of $44.1 million for the second quarter ended June 30, 2026.
Erasca (ERAS) reported a widened net loss for the second quarter ended June 30, 2026. The biotechnology company recorded a loss of $44.1 million, or $0.14 a share, compared to a loss of $33.9 million, or $0.12 a share, in the same period last year.
The increase in losses followed a rise in operational spending. Research and development expenses rose to $35.9 million for the quarter, up from $21.2 million in the second quarter of 2025. General and administrative expenses also increased to $11.7 million from $9.5 million during the prior-year period.
Capital infusions supported the company's liquidity position. Cash, cash equivalents, and marketable securities rose to $384.3 million as of June 30, 2026, from $341.8 million as of December 31, 2025.
Erasca executed two significant capital raises during the first half of the year. The company completed an upsized public offering in July 2026 that raised approximately $632.5 million in gross proceeds. This followed a previous upsized offering in January 2026 of approximately $258.8 million.
Clinical developments continued for the company's lead candidates. Updated preliminary data announced in July 2026 showed that ERAS-0015 demonstrated a 57% uORR 8wk in 2L+ KRAS G12X pancreatic ductal adenocarcinoma.